IRSL, Paris
Nous avons développé une approche innovante pour créer du tissu lymphoïde humain in vitro, en utilisant l’organisation des cellules mésenchymateuses et des PBMC. Ce projet nécessite désormais la consolidation de la méthode et le développement de tests fonctionnels pour le contrôle qualité et la mesure de l’activité des cellules T, B et stromales.
IRSL, Paris
À l’aide de différents modèles murins génétiquement modifiés et en collaboration avec l’INSERM U970/PARCC, nous avons découvert qu’un lipide bioactif est nécessaire à la différenciation des cellules dendritiques de la muqueuse (FDC) (manuscrit en cours de rédaction). Le projet vise désormais à déterminer l’identité du ou des récepteurs impliqués, leur spécificité cellulaire et la voie de signalisation mise en jeu.
CRI, Hopital Bichat, Paris
A one-year (renewable) post-doctoral position is available in the laboratory of Prof. Jean-Michel Sallenave, team ‘Immune signaling in cancer and infection’. The projects aim to study, in the context of cystic fibrosis, host-Pseudomonas aeruginosa molecular and cellular interactions in pulmonary inflammation in vitro and in vivo. Specifically, the project will evaluate the role of bacterial virulence factors and that of innate and adaptive immunity in vaccine protocols against P.aeruginosa.
PARCC, Paris
The successful candidate will join the Kidney, Vessels, Inflammation and Metabolism (KVIM) team, which studies how immune, vascular Inflammation and Metabolism (KVIM) team, which studies how immune, vascular and metabolic pathways shape kidney injury and fibrosis. We investigate the cellular and molecular mechanisms that drive human kidney diseases, from early injury to organ failure.
Université Paris Cité, Paris
The successful candidate will join the Kidney, Vessels, Inflammation and Metabolism (KVIM) team, which studies how immune, vascular and metabolic pathways shape kidney injury and fibrosis. We investigate the cellular and molecular mechanisms that drive human kidney diseases, from early injury to organ failure. The postdoctoral project will focus on understanding how epithelial metabolic programs shape signalling with fibroblasts and immune cells in the fibrotic kidney niche, using both experimental models and human samples.
Center of Structural Biology, Montpellier
The Intelligent Biohybrids Group at INSERM/CBS Montpellier is recruiting a postdoctoral researcher to develop a new class of programmable bacterial therapeutics for lung cancer, within the INCa PLBIO-funded project "Advancing lung cancer treatment through inhaled biohybrid technologies". The project combines synthetic biology, biohybrid materials, pulmonary drug delivery, and cancer immunotherapy to engineer living medicines capable of sensing the tumour microenvironment and producing therapeutic biologics directly within lung tumours.
CEEVEC, Marseille
In collaboration with the management committee, the research engineer will ensure the scientific, technical and administrative functioning of CEEVEC (center of expertise and experimentation on extracellular vesicles), he/she will support the users and will contribute to the technological development and valorization of the platform and EVs Azur-Provence network.
IAME, Paris
The position falls within a quantitative microbiology project focused on the fine-scale, high-throughput analysis of interactions among microorganisms. The successful candidate will carry out targeted experiments to test hypotheses and predictions derived from theoretical models.
CIML - Centre d’Immunologie de Marseille-Luminy
The successful candidate will join an internationally recognized research institute (CIML, Marseille) within a highly collaborative and multidisciplinary environment. The project provides access to state-of-the-art facilities in cellular immunology, virology, advanced imaging, and BSL-3 infrastructure.
Pathogenesis and Control of Chronic and Emerging Infections (PCCEI), Montpellier
Control of Plasmodium vivax is a major public health challenge due to uncertainty in the efficacy and safety of treatment regimens against P. vivax, and a difficulty in identifying patients carrying P. vivax parasites for targeted treatment. We are seeking two post-doctoral candidates to analyse the efficacy and safety of P. vivax treatment regimens, and to quantify the impact of targeted public health interventions on P. vivax incidence and prevalence.